IP Library Granted Patent US 10,436,803
Granted Patent B2
US 10,436,803 · App. 13/338,123 · Granted Oct 8, 2019

Quantitation of insulin by tandem mass spectrometry of insulin B chain

Inventors: Zhaohui Chen (Las Flores, CA); Nigel Clarke (Oceanside, CA)
Assignee: Quest Diagnostics Investments Incorporated
G01N33/74G01N33/49G01N33/6848G01N2333/62H01J49/004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,436,803
App. No.
13/338,123
Granted
Oct 8, 2019
Kind
B2
Abstract

Methods are described for determining the amount of insulin in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying insulin in a biological sample utilizing purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.

Claims (16)

1. A method for determining the amount of insulin in a biological sample by tandem mass spectrometry, the method comprising:

(a) subjecting the sample to conditions suitable to generate insulin B chains from insulin;

(b) processing the sample from step (a) to obtain a fraction enriched in insulin B chains;

(c) subjecting the enriched insulin B chains to an ionization source under conditions suitable to generate one or more insulin B chain ions detectable by mass spectrometry;

(d) selecting and fragmenting a precursor ion with a mass to charge ratio (m/z) of 686.8±0.5; and

(e) determining the amount of one or more insulin B chain fragment ions that result from step (d) by tandem mass spectrometry,

wherein the amount of ions determined in step (d) is related to the amount of insulin in said sample.

2. The method of claim 1 , wherein said processing of step (b) comprises enriching insulin B chains by solid phase extraction (SPE).

3. The method of claim 1 , wherein said processing of step (b) comprises enriching insulin B chains by high performance liquid chromatography (HPLC).

4. The method of claim 1 , wherein said biological sample comprises a human plasma or serum sample.

5. The method of claim 1 , wherein said ionization source is an electrospray (ESI) ionization source.

6. The method of claim 1 , wherein said sample is subjected to acidic conditions prior to ionization in positive ion mode.

7. The method of claim 6 , wherein subjecting said sample to acidic conditions comprises subjecting said sample to formic acid.

8. The method of claim 1 , wherein said one or more ions determined in step (d) comprise one or more fragment ions selected from the group consisting of ions with mass to charge ratios (m/z) of 906.0±0.5, 825.0±0.5, 768.5±0.5, 753.0±0.5, and 703.0±0.5.

9. The method of claim 1 , wherein the ions determined in step (d) comprise one or more ions from the group consisting of ions with m/z of 768.5±0.5 and 753.0±0.5.

10. The method of claim 1 , wherein said fragmenting is conducted with a collision energy within the range of 10 to 25 eV, inclusive.

Assignments (2)
ENTITY CONVERSION Recorded Jan 15, 2025
From: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
To: QUEST DIAGNOSTICS INVESTMENTS LLC
Reel/Frame 069930/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2012
From: CHEN, ZHAOHUI; CLARKE, NIGEL
To: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
Reel/Frame 027800/0394 →
Continuity (2)
Provisional Application 61427749 · Dec 28, 2010
Related Publication 20120164741A1 · Jun 28, 2012
Cited By (2)
US 12,372,539 US 12,493,049